SecBot SecBot
SECBOTREPLAY Home › Report › MRNA

MRNA · Rothschild & Co double downgraded Moderna from Neutral to Sell on Sep…

Moderna, Inc. · ANALYST-DOWNGRADE filed Sep 3, 2026 at 07:50 ET

At the news

BEARISHIMPACT 6/10

ANALYST-DOWNGRADE filed Sep 3, 2026 at 07:50 ET

Rothschild & Co double downgraded Moderna from Neutral to Sell on Sep 3, 2026, slashing the price target from $40 to $81 (a 102.5% increase but representing a 46.3% downside from the current price of $150.81). The firm carries a 57% accuracy rate on 40 calls and an average return of 3.1%, placing it below the top-tier firms covering MRNA. The consensus stands at a mix of 11 Buy, 17 Hold, 2 Sell, with a mean target of $112.56 implying a 25.4% downside. Analyst activity over the past 30 days shows 3 upgrades vs 1 downgrade, but EPS revisions for FY0 are net positive (13 up, 5 down), suggesting some improving fundamental expectations. Insiders have been selling heavily, notably CEO Stephane Bancel sold $28.74M in August 2026, while institutional moves include Citadel trimming by 39.9% and JPMorgan trimming 36.4%, though Norges Bank opened a $211.9M new position. Short interest stands at 62.7% of float, indicating heavy bearish positioning. The Rothschild call is contrarian, a rare double downgrade from a below-top-tier firm, but the massive insider sales and institutional trimming lend support to the bearish stance.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access